Autolus Therapeutics (AUTL) Capital Expenditures (2018 - 2025)

Autolus Therapeutics (AUTL) has 8 years of Capital Expenditures data on file, last reported at -$885000.0 in Q4 2025.

• Quarterly Capital Expenditures fell 107.96% year-over-year to -$885000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19.0 million (down 13.73% YoY) and the FY2025 annual result came in at $19.0 million, down 13.73% from the prior year.
• Capital Expenditures declined to -$885000.0 in Q4 2025, from $4.4 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $11.1 million in Q4 2024 to a low of -$885000.0 in Q4 2025.
• A 5-year average of $3.6 million and a median of $2.8 million in 2021 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 1385.23% in 2025, down 107.96% in 2025.
• Tracing AUTL's Capital Expenditures over 5 years: stood at $1.6 million in 2021, then slumped by 60.06% to $633000.0 in 2022, then soared by 133.33% to $1.5 million in 2023, then surged by 652.34% to $11.1 million in 2024, then sank by 107.96% to -$885000.0 in 2025.
• The last three Capital Expenditures figures came in at -$885000.0 (Q4 2025), $4.4 million (Q3 2025), and $7.3 million (Q2 2025), per Business Quant data.